NPH biosimilar
Selected indexed studies
- Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study. (Diabetes Obes Metab, 2023) [PMID:36708333]
- Higher Order Structure Differences Among Insulin Crystalline Drugs Revealed by 2D heteronuclear NMR. (ChemMedChem, 2024) [PMID:39116305]
- Production costs and potential prices for biosimilars of human insulin and insulin analogues. (BMJ Glob Health, 2018) [PMID:30271626]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Pharmacokinetic and pharmacodynamic equivalence of Biocon's biosimilar insulin N with US-licensed Humulin® N formulation in healthy subjects: Results from the RHINE-2 (Recombinant Human INsulin Equivalence-2) study. (2023) pubmed
- Higher Order Structure Differences Among Insulin Crystalline Drugs Revealed by 2D heteronuclear NMR. (2024) pubmed
- Production costs and potential prices for biosimilars of human insulin and insulin analogues. (2018) pubmed
- Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France. (2021) pubmed
- Trends in Insulin Types and Devices Used by Adults With Type 2 Diabetes in the United States, 2016 to 2020. (2021) pubmed
- Human versus Analogue Insulin for Youth with Type 1 Diabetes in Low-Resource Settings (HumAn-1): protocol for a randomised controlled trial. (2025) pubmed
- Descriptive Analysis of Long- and Intermediate-Acting Insulin and Key Safety Outcomes in Adults with Type 2 Diabetes Mellitus. (2019) pubmed
- Economic evaluation of insulin glargine compared with human insulin for youth with type 1 diabetes in Tanzania and Bangladesh. (2026) pubmed